Valuation: Vista Pharmaceuticals Limited

Market Cap 376M 3.96M 3.55M 3.26M 2.96M 5.53M 5.63M 38.91M 15.62M 198M 14.86M 14.55M 624M P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 443M 4.66M 4.18M 3.84M 3.48M 6.51M 6.63M 45.81M 18.39M 233M 17.5M 17.13M 735M EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
09-12 Vista Pharmaceuticals Limited Announces Resignation of Barkha Jain from Company Secretary and Compliance Officer, Effective September 4, 2026 CI
08-14 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
02-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-03 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
13/08/25 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
16/07/25 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
30/05/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
19/02/25 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
12/02/25 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
13/11/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
13/08/24 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
28/05/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
10/02/24 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
1 day-3.72%
1 week+6.34%
1 month-1.58%
3 months-6.33%
6 months-19.77%
Current year-23.71%
1 week 5.55
Extreme 5.55
6.5
1 month 5.32
Extreme 5.32
6.94
Current year 5.32
Extreme 5.32
8.87
1 year 5.32
Extreme 5.32
10.1
3 years 5.32
Extreme 5.32
19.32
5 years 5.32
Extreme 5.32
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 76 02/01/2014
Director/Board Member 87 16/06/1993
Director/Board Member 76 02/02/2010
Change 5-day change 1-year change 3-year change Capi.($)
-3.72%+6.34%-36.76%-57.47% 4.03M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.50%+5.94%+38.25%+70.36% 426.19B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2024 2025
Net sales 103M 1.08M 970K 893K 809K 1.51M 1.54M 10.64M 4.27M 54.12M 4.07M 3.98M 171M 101M 1.06M 950K 874K 792K 1.48M 1.51M 10.42M 4.18M 53M 3.98M 3.9M 167M
Net income -45.12M -475K -426K -391K -355K -663K -675K -4.67M -1.87M -23.73M -1.78M -1.75M -74.85M -46.49M -490K -438K -403K -365K -683K -696K -4.81M -1.93M -24.45M -1.84M -1.8M -77.12M
Net Debt 78.7M 829K 742K 683K 619K 1.16M 1.18M 8.14M 3.27M 41.4M 3.11M 3.04M 131M 66.71M 703K 629K 579K 524K 980K 999K 6.9M 2.77M 35.09M 2.64M 2.58M 111M
Projected Income Statement - Annual - Vista Pharmaceuticals Limited
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
30/10/26 ₹6.210 -3.72% 2,884
29/10/26 ₹6.450 +5.05% 22,495
28/10/26 ₹6.140 +4.07% 2,265
27/10/26 ₹5.900 +3.33% 318
26/10/26 ₹5.710 -2.23% 5,196
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock